An FDA advisory committee surprised observers on Wednesday night, voting 7-2 to endorse Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug despite FDA doubts and the committee’s own rejection of the drug six months earlier.
Source: Drug Industry Daily